Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Bioheart, Inc. (BHRT)

BHRT RSS Feed
Add BHRT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator JoegerInvest, Gaintrader, HybridTrader, BioheartInc
Search This Board:
Last Post: 9/19/2014 3:36:25 PM - Followers: 147 - Board type: Free - Posts Today: 9

A COMMITMENT TO EXCELLENCE

Bioheart, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 

MyoCell 

MyoCell SDF-1 


MyoCath


AdipoCell

Bioheart’s lead product candidate is MyoCell®, a muscle stem cell therapy that is intended to improve cardiac function months or even years after a patient has suffered severe heart damage due to a heart attack.

MyoCell SDF-1 has received approval from the FDA to begin human clinical trials and is intended to be an improvement to MyoCell.

The MyoCath is a disposable needle injection catheter used for the delivery of biologic solutions to a targeted treatment site within the myocardium, the inner wall of the heart. 

Adipose (fat) tissue is readily available and has been shown to be rich in microvascular, myogenic and angiogenic cells.  Bioheart has recently applied to the FDA to begin trials using adipose derived stem cells or AdipoCell™ in patients with chronic ischemic cardiomyopathy.  

 


The Bioheart Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease.We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.

 

.

Management:

Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
 
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.
 

**Important: Mike Tomás' personal StemCellCEO blog!**
 

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.
 

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by Amazon.com, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame
 

 

Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Charles A. Hart  53 Director
Sam Ahn  59 Director
Kristen Comella  37 Director, Chief Scientific Officer
Sheldon T. Anderson 63 Director
     

Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 
    
BHRT - Daily Candlesticks

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BHRT
Current Price
Volume:
Bid Ask Day's Range
Wiki
BHRT News: Amended Statement of Changes in Beneficial Ownership (4/a) 08/14/2014 01:01:15 PM
BHRT News: Amended Statement of Changes in Beneficial Ownership (4/a) 08/14/2014 12:58:49 PM
BHRT News: Statement of Changes in Beneficial Ownership (4) 08/13/2014 11:38:10 AM
BHRT News: Statement of Changes in Beneficial Ownership (4) 08/13/2014 11:37:05 AM
BHRT News: Statement of Changes in Beneficial Ownership (4) 08/06/2014 09:24:44 AM
PostSubject
#10184  Sticky Note Small Cap Voice Interview with BioHeart HybridTrader 06/25/14 06:27:59 PM
#6744  Sticky Note Bioheart Announces Positive 6 Month Data From Angel Gaintrader 04/03/14 05:59:37 PM
#5610  Sticky Note Bioheart's CEO Mike Tomás blog. JoegerInvest 03/08/14 04:51:07 PM
#11192   Thanks for being more clear this time around. BrownRickRoss 09/19/14 03:36:24 PM
#11190   Opened on $28.16 cents traded (1024 shares), supposedly Hopalongstocks 09/19/14 12:50:17 PM
#11186   Sorry not understanding what you're saying. Too vague. BrownRickRoss 09/19/14 10:20:58 AM
#11185   Wow excellent work Gain! I think we have BrownRickRoss 09/19/14 10:19:06 AM
#11184   Agreed, with positive revenue growth, reduced debt, and Gaintrader 09/19/14 09:36:10 AM
#11183   One day- a trend does not a maketh, Hopalongstocks 09/18/14 07:54:28 PM
#11182   Does anyone know the timeframe of when will ggupta1767 09/18/14 06:29:41 PM
#11181   I stand by my point. It was perfect BrownRickRoss 09/18/14 05:35:26 PM
#11180   Great day. Up on good volume. Pushing for jj3223 09/18/14 04:16:52 PM
#11179   Good day. Look forward to more tomorrow IMO. GLTA andyshow 09/18/14 04:13:09 PM
#11178   Nice! Just a matter of time. Life changer Pierrocks 09/17/14 03:10:45 PM
#11176   Awesome read about bone marrow stem cells injected andyshow 09/17/14 04:50:25 AM
#11175   Technical analysis DEATH CROSS setting up - it's Hopalongstocks 09/16/14 11:01:16 PM
#11174   Opinion accepted, but not agreed to. JWMN 09/16/14 10:35:12 PM
#11173   Time for new leadership at Bioheart? Ringohalfcan 09/16/14 08:29:58 PM
#11172   I for one care about the status of JWMN 09/16/14 08:26:04 PM
#11170   ONE PATIENT "enrolled" and then NOTHING. It's been Hopalongstocks 09/16/14 08:11:03 PM
#11169   Can't move forward in the past 4 years?!? andyshow 09/16/14 08:03:00 PM
#11168   Phase I?? What difference does a phase I Hopalongstocks 09/16/14 07:59:50 PM
#11167   From the last 10Q "We have completed the Phase andyshow 09/16/14 07:51:54 PM
#11166   I am going to go out on limb JWMN 09/16/14 07:45:19 PM
#11165   "and trials moving along."??? Really? Which ones? Hopalongstocks 09/16/14 07:45:08 PM
#11164   Perseverance is one major element of success. JWMN 09/16/14 07:39:04 PM
#11163   I agree. JWMN 09/16/14 07:34:45 PM
#11162   Not much of a concern when your revenues HybridTrader 09/16/14 07:29:56 PM
#11157   A 2.4 cent stock price and cash broke Hopalongstocks 09/16/14 06:51:02 PM
#11154   Lol you definitely were. andyshow 09/16/14 06:41:38 PM
#11153   I don't need to type 1million words to andyshow 09/16/14 06:41:12 PM
#11152   See I was close lol jj3223 09/16/14 06:38:21 PM
#11151   And? So? It's still 100% true. What serious Hopalongstocks 09/16/14 06:34:13 PM
#11150   03/08/2014 you said "I don't see a single andyshow 09/16/14 06:18:21 PM
#11149   Agree, down 4% on the "big PR news" Hopalongstocks 09/16/14 06:11:00 PM
#11148   Lol andyshow 09/16/14 05:56:46 PM
#11147   " but yet very little selling despite the Hopalongstocks 09/16/14 05:05:33 PM
#11146   I suspect the same. IMO I've said it andyshow 09/16/14 04:56:07 PM
#11145   I suspect we see a nice GREEN day tomorrow$$$ Pierrocks 09/16/14 04:54:43 PM
#11144   Revenue this quarter will hopefully approach 1mil andyshow 09/16/14 04:46:35 PM
#11143   I predict approx. $1 million in revenue off jj3223 09/16/14 04:45:34 PM
#11142   Yup. I've only held shares since last summer, Gsdubb 09/16/14 04:42:58 PM
#11141   Thank you for the updates. HybridTrader 09/16/14 04:10:19 PM
#11140   Would be perfect day for convertible share dumping, BrownRickRoss 09/16/14 03:30:57 PM
#11139   Exciting news for sure. This screams REVENUE at me!! andyshow 09/16/14 01:22:46 PM
#11138   Thank you for the excellent news. JWMN 09/16/14 10:54:51 AM
#11135   What "financing"? Dilutive, toxic, convertible debt deals? They Hopalongstocks 09/16/14 10:25:55 AM
#11134   Oh- and please give the following: Hopalongstocks 09/16/14 10:21:44 AM
#11132   Please post the following for us: Hopalongstocks 09/16/14 10:16:51 AM
#11131   51 MILLION is the entire population of South Hopalongstocks 09/16/14 10:14:03 AM
#11130   Better news would be financing to complete SDF cjlopez 09/16/14 09:53:19 AM
#11129   I wonder why Bioheart didn't PR this? BrownRickRoss 09/16/14 09:47:18 AM
#11128   We are proud to announce the grand opening BioheartInc 09/16/14 09:46:31 AM
PostSubject